

Special Issue: Next Generation Therapeutics

# Mechanisms of cooperation in cancer nanomedicine: towards systems nanotechnology

Sabine Hauert<sup>1,2,3</sup> and Sangeeta N. Bhatia<sup>1,2,4,5,6</sup>

<sup>1</sup> Harvard–MIT Division of Health Sciences and Technology, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

<sup>2</sup> David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

<sup>3</sup> Engineering Mathematics, University of Bristol, Bristol BS8 1TR, UK

<sup>4</sup> Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

<sup>5</sup> Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA

<sup>6</sup> Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

**Nanoparticles are designed to deliver therapeutics and diagnostics selectively to tumors. Their size, shape, charge, material, coating, and cargo determine their individual functionalities. A systems approach could help predict the behavior of trillions of nanoparticles interacting in complex tumor environments. Engineering these nanosystems may lead to biomimetic strategies where interactions between nanoparticles and their environment give rise to cooperative behaviors typically seen in natural self-organized systems. Examples include nanoparticles that communicate the location of a tumor to amplify tumor homing or self-assemble and disassemble to optimize nanoparticle transport. The challenge is to discover which nanoparticle designs lead to a desired system behavior. To this end, novel nanomaterials, deep understanding of biology, and computational tools are emerging as the next frontier.**

## Cooperative nanosystems

Cancer is one of the leading causes of death worldwide. To address cancer, bioengineers are designing nanoparticles that can deliver treatments and diagnostics selectively to tumors [1,2]. Their size, typically between 5 and 500 nm, allows them to escape the leaky vessels in tumors [3]. Focus has been on engineering the functionalities of individual nanoparticles to improve transport [4]; target the tumor vasculature [5,6] or extracellular matrix (ECM) [7]; deliver therapeutics [8,9], diagnostics [10] or heat [11,12] to the tumor environment; and reprogram cancer cells [13] or the immune system [14].

The behavior of each nanoparticle depends on its design and the resulting interactions in the body. The collective behavior of trillions of such nanoparticles interacting in a complex tumor environment can define their success as

diagnostic or treatment agents [15]. Predicting and engineering these collective behaviors is empirical and not intuitive. For example, nanoparticles that are optimized to bind strongly to and accumulate in cancer cells mostly accumulate in the first cells they encounter after leaking into the tumor environment. The resulting collective behavior is poor tissue penetration, with deep-seeded tumor cells left untreated, otherwise called a binding-site barrier [16–18]. Weaker nanoparticle binding, although detrimental to the function of the individual nanoparticle, could lead to a better system outcome. Further engineering of these behaviors could result in emergent cooperative behaviors typically seen in self-organized systems.

Self-organized systems in nature, including social insects, animals, humans, and cells, are able to perform complex behaviors such as amplification, optimization, mapping, structure assembly, collective motion, synchronization, and decision making, through the local interactions of many simple agents and their environment [19–22]. The field of swarm robotics [23,24] has long taken inspiration from nature to engineer minimal robots that use simple rules to interact with their neighbors and local environment to solve complex real-world problems [25–27]. Behaviors demonstrated in nanomedicine include self-assembly of nanoparticles to anchor imaging agents in tumors [28,29]; disassembly of nanoparticles to increase tissue penetration [30,31]; nanoparticles that compute the state of a tumor [32]; nanoparticle-based remodeling of tumor environments to improve secondary nanoparticle transport [33]; and nanoparticle signaling of tumor location to amplify the accumulation of other nanoparticles in tumors [34].

Engineering and predicting the collective behavior of large numbers of nanoparticles interacting in complex tumor environments is non-intuitive, even for simple nanoparticle designs. Using a systems approach, bioengineers could automatically explore nanoparticle designs using crowdsourcing (<http://nanodoc.org>) and machine learning [35], model the resulting collective behavior in simulation [4,16,17,36], automatically test the best candidates experimentally through fast prototyping of both

Corresponding author: Bhatia, S.N. ([sbhatia@mit.edu](mailto:sbhatia@mit.edu)).

Keywords: swarming; cooperation; nanoparticles; systems nanotechnology; cancer.

0167-7799/

© 2014 Elsevier Ltd. All rights reserved. <http://dx.doi.org/10.1016/j.tibtech.2014.06.010>

the nanoparticles [37,38] and their environment [39], and finally validate the collective behaviors in vivo with feedback provided by high-resolution imaging [40]. Expertise in nanomaterials, deep understanding of cancer biology, and advances in the modeling and automation of nano-systems are enabling the first steps in this direction.

Finally, lessons learned from the design of cooperative nanosystems could prove useful in the engineering of natural swarms, such as cells of the immune system [41] or synthetic bacteria [42], to improve tumor treatment and diagnostics. Overall, a systems approach to understand and engineer self-organized systems has the potential to result in behaviors that go beyond the functionalities of the individual agents and towards efficient, modular, and predictable outcomes.

### Nanoparticle behaviors


A large variety of nanoparticles have been engineered to deliver therapies and diagnostics to tumors. The design of a nanoparticle and its interactions with the environment define its behavior. The composition of each nanoparticle can be summarized by its main features in terms of initial size, shape, charge, coating, cargo, and material, the combination of which determines its ability to move and interact with the environment (Figure 1) [43,44].

The size of a nanoparticle has been shown to influence its circulation time, extravasation, interstitial diffusion, and ability to be internalized by cells [45,46]. Nanoparticles smaller than 5 nm tend to escape the bloodstream into tissues throughout the body [47,48]. They are rapidly filtered by the kidneys and cleared in the urine. As a result,

small nanoparticles have a short circulation time on the order of minutes, rapid entry into tumors, and fast diffusion through the tumor tissue. Nanoparticles that reach the edge of a solid tumor can be carried out due to the gradient in hydrostatic pressure caused by the physiology of the tumor relative to that of the surrounding healthy tissue, thereby making their retention more challenging [3]. Nanoparticles larger than 5 nm and up to 500 nm are, in some cases, able to remain in circulation for a longer time and accumulate in solid tumors by escaping through the enlarged pores in angiogenic vessels. Such passive targeting of nanoparticles due to porous angiogenic endothelium and dysfunctional lymphatic drainage, observed in some tumors, has been called the enhanced permeability and retention (EPR) effect [49]. Once in the tumor, the slow diffusion of larger nanoparticles and the difficulty navigating the ECM tend to limit their ability to penetrate tumor tissue [50]. The size of a nanoparticle also limits its ability to be internalized by cells and data indicate that different sizes could be trafficked via different endocytic pathways [44].

The shape and modulus of nanoparticles can also impact cellular uptake [51]. Nanoparticles with high aspect ratios and particles that are rigid have been shown to accumulate more slowly in macrophages than smaller, flexible particles, thereby reducing their clearance time from the blood. In situations where uptake is important, such as in tumor environments, spherical nanoparticles have thus far proven more efficient.

The charge of a nanoparticle also impacts its circulation time. Charged nanoparticles are rapidly opsonized and cleared by the immune system [52]. Passivating coatings



**Figure 1.** Nanoparticle behaviors. Nanoparticle designs, in terms of size, shape, modulus, charge, material, surface, and cargo, as well as their interactions in the body, determine their individual behavior.

such as polyethylene glycol have been used to shield the charge of nanoparticles, improve their circulation time on the order of days, and result in their accumulation in tumor tissue [43]. Similarly, phagocytic uptake can be minimized by coating nanoparticles with a 'self-peptide' derived from the human 'don't eat me' receptor CD47 [53]. Once in tumor tissue, charged nanoparticles are preferentially taken up by tumor cells relative to uncharged particles. Researchers have been addressing this dichotomy by designing nanoparticles that shed their neutral coatings to display a charged interior upon entering the tumor environment based on pH or enzymatic activity [54–56].

Beyond charge, nanoparticle surfaces can be engineered to display targeting ligands [5,7,57] including peptides [58], antibodies [59], aptamers [60], and small molecules [61]. Receptors that are expressed at high levels on certain tumor cells can serve as targets that drive the binding and intracellular delivery of nanoparticles [6]. For small nanoparticles, targeting has proven useful in anchoring nanoparticles in the tumor environment, resulting in increased accumulation over time [62]. Recently, nanoparticles decorated with ligands expressing a CendR domain have been shown to activate the neuropilin-1 receptor and subsequently increase tissue penetration by initiating a transcellular active transport pathway [63]. The effect can be made specific to tumor tissue by adding a targeting domain to the peptide. Receptors overexpressed on angiogenic endothelial cells have been used as vascular 'zip codes' to direct and capture circulating nanoparticles and concentrate them in tumor environments [6] or can serve as an antiangiogenic target towards the normalization of the vascular bed [3,64]. Nanoparticles have also been engineered to target the ECM, either to improve the retention of nanoparticles [65] or to degrade the ECM to improve drug permeation in tumors [66]. Finally, nanoparticles can be engineered to target T cells and enhance immune responses towards tumors [14,67].

One other design benefit that nanoparticles offer is the capacity to shield materials that would otherwise be toxic or degraded in the body. The therapeutic cargo may then be carried to the tumor where it will be released or activated, thereby minimizing systemic side effects while improving effectiveness despite low doses. Cargos transported by nanoparticles include chemotherapies [8,9]; small interfering RNA (siRNA) for knockdown of gene expression in tumor cells [13,68]; antiangiogenic agents [64,69]; agents that are disruptive to the ECM [70]; imaging agents [1,10]; and adjuvants to activate the immune system [14].

The ability of nanoparticles to react to their environment is directly connected to their material composition [71]. Nanoparticles can be engineered to release cargos in an open-loop manner at a predetermined rate based on material erosion, or cargo diffusion through the nanoparticle matrix or pores [72–74]. To increase the level of control, materials can release their cargo or change their physical properties in response to local stimuli in tumor microenvironments, such as pH or enzymatic activity [55,75–77]. Energy-sensitive materials can be activated by global signals including magnetic fields [78–80], sound [81], or light [11,82,83], that power them to move, emit light, release a cargo or heat.


Overall, the ability of nanoparticles to sense, move, and act in the body is determined by their design and interactions with the environment. Engineering the behavior of nanoparticles has become increasingly possible thanks to deep understanding of biology and nanoparticle transport, and the impressive toolbox of nanoparticle modifiers available to bioengineers.

### Collective behaviors

In other fields, engineering collective behavior is necessary to achieve a desired system outcome. Engineering the collective behavior of nanoparticles may similarly lead to a better system outcome. Most nanoparticle systems cooperate implicitly, each nanoparticle is designed to optimize its individual functionality [84]. The collective impact of the nanoparticles as treatment or imaging agents is assumed to be the sum of the independent nanoparticle effects. Understanding the system-level behavior of implicit cooperators may add insight that improves predictions. Emphasis could be placed on studying whether the nanoparticles can collectively distribute throughout a tumor environment or accumulate at effective levels in, or around, targeted cells [4]. Likewise, combination therapies aimed at preventing resistance can comprise different types of nanoparticle that independently target cells in the tumor [85,86].

Nanoparticles that interact physically have a more direct means of cooperation. These systems typically self-assemble or disassemble to modify their kinetics or collectively transport combined treatment and imaging agents to tumors. Rapidly diffusing imaging agents are able to anchor in tumors by binding to gold nanoparticles injected previously that have had time to accumulate there due to the EPR effect [29]. Small (10 nm) gold nanoparticles engineered to release conjugated doxorubicin in acidic tumor environments can subsequently self-assemble to form larger gold aggregates that are then used for photothermal therapy [28,87]. *In vitro* experiments show how nanoparticles that self-assemble in response to enzymatic activity may be able to perform logic computations towards the diagnosis of tumor state [88]. Larger nanoparticles (100 nm) are able to disassemble into smaller nanoparticles once inside the tumor environment in response to enzymatic activity, thereby improving their circulation time, accumulation in the tumor, and ability to penetrate deep into the tissue [31]. Other multistage nanoparticles, including nested nanoparticles, mother ships, and nanocells, are able to overcome transport barriers through the release of nano-based components in tumor environments [64,89,90].

In contrast to collective behaviors mediated by direct interactions between nanoparticles, many swarm systems found in nature communicate by modifying the environment. This concept is called stigmergy [19]. Ants deposit and sense chemical signals to form trails to sources of food [20]. Termites are able to build complex structures by modifying and locally sensing their physical environment [27]. In a similar way, nanoparticles have been designed to modify their physical environment or deposit chemical signals. Gold nanorods that accumulate in a tumor, upon heating with near-IR (NIR) light to sub-lethal temperatures,



**Figure 2.** Mechanisms of cooperation in nanosystems. **(A)** Implicit cooperation. Each nanoparticle works individually to improve the overall tissue distribution (top) or work as a combination therapy (bottom). **(B)** Direct cooperation. Physical interactions enable nanoparticles to self-assemble (top) and disassemble (bottom) towards improved nanoparticle transport and retention in tumors. **(C)** Stigmergic cooperation. Nanoparticles interact through the environment either by modifying the environment to improve the transport of secondary nanoparticles (left) or by depositing a signal (right). Signaling nanoparticles can emit energy and chemicals or coerce a biological response from the tumor environment that can be received by a secondary nanoparticle.

can improve perfusion of angiogenic vessels and in some cases upregulate receptors used in targeting. This in turn improves the delivery of a second wave of nanoparticles, such as liposomes or magnetic nanoworms, to tumors for treatment and imaging purposes [33,82]. Likewise, nanoparticles that aim to normalize the vascular bed or degrade the ECM can improve the transport of secondary nanoparticles [3,66].

Nanoparticles can also communicate through the environment by depositing a signal according to two possible modes of action. In the first, nanoparticles are able to release either a cargo or energy that can directly interact with other nanoparticles. This approach offers an important advantage: nanoparticle communication can be engineered to be orthogonal to the host system. As an example, gold nanorods activated through NIR light emit heat in tumors to trigger the release of chemotherapeutics contained in thermally sensitive drug carriers [91]. Unfortunately, the scales at which nanoparticles function make it difficult for a chemical cargo to encounter a second nanoparticle in the environment. By contrast, biological systems have built-in mechanisms to amplify signals; coercing biological cascades can result in longer-range communication systems. Gold nanorods heated through NIR light can cause a clotting cascade in tumors [34]. This biological cascade serves as a signal to communicate the location of the tumor to circulating nanoparticles loaded with chemotherapeutics. To achieve this outcome, the receiving nanoparticle, here a liposome or nanoworm, is targeted


to a byproduct of the coagulation cascade (the transglutaminase FXIII). This communication strategy leads to a 40-fold increase in the amount of chemotherapeutic delivered to the tumor compared with a non-communicating system [34].

Nanoparticles can cooperate implicitly, directly through self-assembly and disassembly, or through stigmergy (Figure 2). These behaviors have been useful in improving nanoparticle transport, accumulation, and distribution in tumor tissues towards treatment and diagnostic applications.

### Systems nanotechnology

A systems approach could help engineer collective behaviors for nanoparticles (Figure 3) [92]. Currently, most nanoparticle systems are engineered based on the desired functionalities of the individual nanoparticles. Designing cooperative behaviors requires bioengineers to initially define the behavior that should be displayed by the nanoparticle collective within its environment of action. Examples include ‘accumulate in all tumor cells at lethal levels, assuming sites of extravasation are no further than 200  $\mu\text{m}$  from the cells’ [16]. The challenge is then to understand which individual nanoparticle designs could give rise to this collective behavior.

Currently, the exploration of nanoparticle designs is conducted by experts with a deep knowledge of the intricacies of cancer nanomedicine. This paradigm is ideal when the collective behavior resulting from a given nanoparticle



**Figure 3.** Systems approach towards nanomedicine. A systems approach could help design the individual nanoparticles that would give rise to desired cooperative behaviors. This requires advances in computational exploration, modeling, and the fast prototyping of experiments before validation *in vivo*.

design and its iterations are well understood. When new designs are needed, or more complex collective behaviors are envisaged, automatic exploration tools built around machine learning and crowdsourcing can help. Mathematical optimization was used to explore formulations, in terms of binding kinetics and diffusion, that would enable targeted nanoparticles to penetrate deep into tumor tissues [16]. Regression analysis was used to explore the impact of nanoparticles' structure on their ability to deliver siRNAs to tumor cells [93]. When the search space is too large, the power of the crowd can enable human-guided exploration of nanoparticle designs. Crowdsourcing has been shown in the past to find solutions to complex scientific problems that were intractable for computers, despite their impressive processing power [94]. NanoDoc (<http://nanodoc.org>), for example, provides an online tool to crowdsource the design of nanoparticles. Using an iterative approach, players design nanoparticle treatments, inject them into a virtual tumor, and continuously improve their design until they are able to achieve a desired collective behavior.

Once provided with a nanoparticle design, computer simulations and mathematical models can help predict their collective behavior. Analytical and Monte Carlo simulations have been used to predict the impact of multi-valency of targeting moieties on the super-selectivity of nanoparticles to cancer cells [95]. Modeling the kinetics of nanoparticle populations in tumors has been demonstrated by several research groups using stochastic and deterministic approaches [16–18,36,96]. The models describe how nanoparticles extravasate, diffuse through the interstitial space, and bind to or are internalized by cancer cells. Ideally, iterations between nanoparticle design and the resulting simulated behavior give rise to general guidelines that can be applied to nanosystems without the need to iterate at length experimentally.

After developing plans for an idealized nanoparticle, these designs must then be engineered. Most often, this step requires deep expertise based on the state of the art in the field. However, automatic tools can help combine nanoparticle features such as size, coating, and cargo in a deterministic fashion [37]. Particle replication in non-wetting

templates (PRINT) technology offers an easy-to-use platform for the design and fabrication of monodisperse particles from a wide range of matrices with complete control over the physicochemical properties of the particle [38]. Combinatorial approaches in designing and synthesizing polymeric systems enable high-throughput synthesis and screening of nanoparticles with desired drug loading, retention in circulation, and targeting. For this purpose, several polymer libraries have been designed [97–99]. Recent work on DNA self-assembly also enables the rapid prototyping of nanoscale structures [100–103].

Testing the collective behavior of nanoparticles is made challenging by the fact that the environment plays such an important role in the rise of emergent behaviors. *In vivo* experiments are an ideal test bed, provided that high-resolution imaging can be performed during the course of the experiment. Multimodal studies of tumor pathophysiology and nanoparticle dynamics can be performed with the help of intravital microscopy in window chambers [104,105]. When *in vivo* experiments are unfeasible, micro-devices can be used that are capable of capturing the essential features of the tumor environment necessary for the emergence of collective nanoparticle behaviors. A tumor-on-a-chip system, in which a tumor-like spheroid is placed in a microfluidic channel, enables real-time analysis of nanoparticle kinetics under physiological flow conditions [106]. Recent technologies, including 3D printing, scaffolding, and cell patterning, layering, and self-assembly, have enabled construction of complex 3D human tissues, including blood and lymph capillary networks, and could be used as a test bed for cooperative nanosystems *in vitro* [39,107,108].

A key grand challenge is the integration of all the technologies needed to provide a complete pipeline from problem definition to clinical translation.

### Concluding remarks and future perspectives

Nanoparticle behaviors result from their individual designs and interactions with the environment. Control of a nanoparticle is enabled by changing its shape, charge, material, coating, and cargo. The behavior of trillions of

nanoparticles *in vivo* determines their success as treatment and diagnostic agents. The field could therefore benefit from increased understanding and systematic approaches to engineering the collective behavior of nanoparticles. Examples of self-organization in nature show that emergent behaviors arise when simple agents interact directly or through the environment and can lead to modular, scalable, and efficient strategies that outperform the capabilities of individual agents. Such concepts are already being used in other fields of engineering, such as swarm robotics.

Designing individual nanoparticles towards a desired cooperative strategy is challenging and could benefit from a systems approach. Such an endeavor would build on advances in computational exploration, simulation, high-throughput design of nanoparticles, and the engineering of experimental test beds *in vitro* and *in vivo*. This approach is now made possible thanks to advances in nanoparticle design and a deeper understanding of biology, which have given rise to the first instances of cooperative nanoparticles that can communicate tumor location, improve transport, and self-assemble or disassemble. The next frontier is to learn from these examples to design biomedical systems that can perform complex tasks such as optimization, computation, decision-making, construction, self-assembly, and collective motion. Strategies of cooperation could go beyond nanoparticles to integrate engineered biological systems including synthetic bacteria and cells of the immune system towards biomedical applications.

#### Acknowledgments

The authors are grateful to Dr Fleming for her help in reviewing the manuscript. They acknowledge support from the Human Frontier Science Program. S.N.B. is a Howard Hughes Medical Institute investigator. This work was supported in part by National Institutes of Health (NIH) U54CA151884, MIT-Harvard Center of Cancer Nanotechnology Excellence, and the Koch Institute Support (core) Grant P30-CA14051 from the National Cancer Institute.

#### References

- Bao, G. *et al.* (2013) Multifunctional nanoparticles for drug delivery and molecular imaging. *Annu. Rev. Biomed. Eng.* 15, 253–282
- Davis, M.E. *et al.* (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. *Nat. Rev. Drug Discov.* 7, 771–782
- Jain, R.K. and Stylianopoulos, T. (2010) Delivering nanomedicine to solid tumors. *Nat. Rev. Clin. Oncol.* 7, 653–664
- Ferrari, M. (2010) Frontiers in cancer nanomedicine: directing mass transport through biological barriers. *Trends Biotechnol.* 28, 181–188
- Brannon-Peppas, L. and Blanchette, J.O. (2012) Nanoparticle and targeted systems for cancer therapy. *Adv. Drug Deliv. Rev.* 64, 206–212
- Ruoslahti, E. *et al.* (2010) Targeting of drugs and nanoparticles to tumors. *J. Cell Biol.* 188, 759–768
- Kanapathipillai, M. *et al.* (2014) Nanoparticle targeting of anti-cancer drugs that alter intracellular signaling or influence the tumor microenvironment. *Adv. Drug Deliv. Rev.* <http://dx.doi.org/10.1016/j.addr.2014.05.005>
- Cho, K. *et al.* (2008) Therapeutic nanoparticles for drug delivery in cancer. *Clin. Cancer Res.* 14, 1310–1316
- Wang, A.Z. *et al.* (2012) Nanoparticle delivery of cancer drugs. *Annu. Rev. Med.* 63, 185–198
- Ryu, J.H. *et al.* (2012) Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy. *Adv. Drug Deliv. Rev.* 64, 1447–1458
- Melancon, M. *et al.* (2011) Cancer theranostics with near-infrared light-activatable multimodal nanoparticles. *Acc. Chem. Res.* 44, 947–956
- Pissuwan, D. *et al.* (2006) Therapeutic possibilities of plasmonically heated gold nanoparticles. *Trends Biotechnol.* 24, 62–67
- Kanasty, R. *et al.* (2013) Delivery materials for siRNA therapeutics. *Nat. Mater.* 12, 967–977
- Moon, J.J. *et al.* (2012) Engineering nano- and microparticles to tune immunity. *Adv. Mater.* 24, 3724–3746
- Taurin, S. *et al.* (2012) Anticancer nanomedicine and tumor vascular permeability: where is the missing link? *J. Control. Release* 164, 265–275
- Hauert, S. *et al.* (2013) A computational framework for identifying design guidelines to increase the penetration of targeted nanoparticles into tumors. *Nano Today* 8, 566–576
- Thurber, G.M. and Weissleder, R. (2011) A systems approach for tumor pharmacokinetics. *PLoS ONE* 6, e24696
- Wittrup, K.D. *et al.* (2012) Practical theoretic guidance for the design of tumor-targeting agents. *Methods Enzymol.* 503, 255–268
- Bonabeau, E. *et al.* (1999) *Swarm Intelligence: From Natural to Artificial Systems*, Oxford University Press
- Camazine, S. *et al.* (2003) *Self-Organization in Biological Systems*, Princeton University Press
- Couzin, I.D. (2009) Collective cognition in animal groups. *Trends Cogn. Sci.* 13, 36–43
- Krause, J. *et al.* (2010) Swarm intelligence in animals and humans. *Trends Ecol. Evol.* 25, 28–34
- Şahin, E. (2005) Swarm robotics: from sources of inspiration to domains of application. In *Swarm Robotics* (Şahin, E. and Spears, W.M., eds), pp. 10–20, Springer
- Winfield, A.F.T. *et al.* (2005) Towards dependable swarms and a new discipline of swarm engineering. In *Swarm Robotics* (Şahin, E. and Spears, W.M., eds), pp. 126–142, Springer
- Hauert, S. *et al.* (2011) Reynolds flocking in reality with fixed-wing robots: communication range vs. maximum turning rate. In *IEEE/RSJ International Conference on Intelligent Robots and Systems*. pp. 5015–5020 IEEE
- Kernbach, S. (2013) *Handbook of Collective Robotics: Fundamentals and Challenges*, Pan Stanford Publishing
- Werfel, J. *et al.* (2014) Designing collective behavior in a termite-inspired robot construction team. *Science* 343, 754–758
- Nam, J. *et al.* (2009) pH-induced aggregation of gold nanoparticles for photothermal cancer therapy. *J. Am. Chem. Soc.* 131, 13639–13645
- Perrault, S.D. and Chan, W.C.W. (2010) *In vivo* assembly of nanoparticle components to improve targeted cancer imaging. *Proc. Natl. Acad. Sci. U.S.A.* 107, 11194–11199
- Godin, B. *et al.* (2011) Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. *Acc. Chem. Res.* 44, 979–989
- Wong, C. *et al.* (2011) Multistage nanoparticle delivery system for deep penetration into tumor tissue. *Proc. Natl. Acad. Sci. U.S.A.* 108, 2426–2431
- Kwong, G.A. *et al.* (2013) Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease. *Nat. Biotechnol.* 31, 63–70
- Park, J-H. *et al.* (2010) Cooperative nanomaterial system to sensitize, target, and treat tumors. *Proc. Natl. Acad. Sci. U.S.A.* 107, 981–986
- von Maltzahn, G. *et al.* (2011) Nanoparticles that communicate *in vivo* to amplify tumour targeting. *Nat. Mater.* 10, 545–552
- Phan, J.H. *et al.* (2009) Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment. *Trends Biotechnol.* 27, 350–358
- Florence, A.T. (2012) “Targeting” nanoparticles: the constraints of physical laws and physical barriers. *J. Control. Release* 164, 115–124
- Abeylath, S.C. *et al.* (2011) Combinatorial-designed multifunctional polymeric nanosystems for tumor-targeted therapeutic delivery. *Acc. Chem. Res.* 44, 1009–1017
- Xu, J. *et al.* (2013) Future of the particle replication in nonwetting templates (PRINT) technology. *Angew. Chem. Int. Ed. Engl.* 52, 6580–6589
- Vickerman, V. *et al.* (2008) Design, fabrication and implementation of a novel multi-parameter control microfluidic platform for three-dimensional cell culture and real-time imaging. *Lab Chip* 8, 1468–1477

- 40 Weissleder, R. and Pittet, M.J. (2008) Imaging in the era of molecular oncology. *Nature* 452, 580–589
- 41 Deisboeck, T.S. and Couzin, I.D. (2009) Collective behavior in cancer cell populations. *Bioessays* 31, 190–197
- 42 Forbes, N.S. (2010) Engineering the perfect (bacterial) cancer therapy. *Nat. Rev. Cancer* 10, 785–794
- 43 Petros, R.A. and DeSimone, J.M. (2010) Strategies in the design of nanoparticles for therapeutic applications. *Nat. Rev. Drug Discov.* 9, 615–627
- 44 Wang, J. *et al.* (2011) More effective nanomedicines through particle design. *Small* 7, 1919–1931
- 45 Dreaden, E.C. *et al.* (2012) Size matters: gold nanoparticles in targeted cancer drug delivery. *Ther. Deliv.* 3, 457–478
- 46 Kievit, F.M. and Zhang, M. (2011) Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. *Adv. Mater.* 23, 217–247
- 47 Choi, H.S. *et al.* (2007) Renal clearance of quantum dots. *Nat. Biotechnol.* 25, 1165–1170
- 48 Longmire, M. *et al.* (2008) Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. *Nanomedicine (Lond.)* 3, 703–717
- 49 Maeda, H. *et al.* (2012) The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging *in vivo*. *Adv. Drug Deliv. Rev.* 65, 71–79
- 50 Perrault, S.D. *et al.* (2009) Mediating tumor targeting efficiency of nanoparticles through design. *Nano Lett.* 9, 1909–1915
- 51 Venkataraman, S. *et al.* (2011) The effects of polymeric nanostructure shape on drug delivery. *Adv. Drug Deliv. Rev.* 63, 1228–1246
- 52 Owens, D.E. and Peppas, N.A. (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. *Int. J. Pharm.* 307, 93–102
- 53 Rodriguez, P.L. *et al.* (2013) Minimal “self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. *Science* 339, 971–975
- 54 Harris, T.J. *et al.* (2008) Protease-triggered unveiling of bioactive nanoparticles. *Small* 4, 1307–1312
- 55 Poon, Z. *et al.* (2011) Layer-by-layer nanoparticles with a pH-sheddable layer for *in vivo* targeting of tumor hypoxia. *ACS Nano* 5, 4284–4292
- 56 Romberg, B. *et al.* (2008) Sheddable coatings for long-circulating nanoparticles. *Pharm. Res.* 25, 55–71
- 57 Kamaly, N. *et al.* (2012) Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. *Chem. Soc. Rev.* 41, 2971–3010
- 58 Pearce, T.R. *et al.* (2012) Peptide targeted lipid nanoparticles for anticancer drug delivery. *Adv. Mater.* 24, 3803–3822 3710
- 59 Julien, D.C. *et al.* (2011) Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer. *MAbs* 3, 467–478
- 60 Yang, L. *et al.* (2011) Aptamer-conjugated nanomaterials and their applications. *Adv. Drug Deliv. Rev.* 63, 1361–1370
- 61 Valencia, P.M. *et al.* (2011) Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. *Biomaterials* 32, 6226–6233
- 62 Timko, B.P. *et al.* (2011) Advances in drug delivery. *Annu. Rev. Mater. Res.* 41, 1–20
- 63 Ruoslahti, E. (2012) Peptides as targeting elements and tissue penetration devices for nanoparticles. *Adv. Mater.* 24, 3747–3756
- 64 Sengupta, S. *et al.* (2005) Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. *Nature* 436, 568–572
- 65 Ji, T. *et al.* (2013) Using functional nanomaterials to target and regulate the tumor microenvironment: diagnostic and therapeutic applications. *Adv. Mater.* 25, 3508–3525
- 66 Waite, C. and Roth, C. (2012) Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. *Crit. Rev. Biomed. Eng.* 40, 21–41
- 67 Silva, J.M. *et al.* (2013) Immune system targeting by biodegradable nanoparticles for cancer vaccines. *J. Control. Release* 168, 179–199
- 68 Hou, K.K. *et al.* (2013) Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides. *ACS Nano* 7, 8605–8615
- 69 Bocci, G. *et al.* (2013) The pharmacological bases of the antiangiogenic activity of paclitaxel. *Angiogenesis* 16, 481–492
- 70 Goodman, T.T. *et al.* (2007) Increased nanoparticle penetration in collagenase-treated multicellular spheroids. *Int. J. Nanomed.* 2, 265–274
- 71 Zhu, L. and Torchilin, V.P. (2013) Stimulus-responsive nanopreparations for tumor targeting. *Integr. Biol. (Camb)* 5, 96–107
- 72 Kost, J. and Langer, R. (2012) Responsive polymeric delivery systems. *Adv. Drug Deliv. Rev.* 64, 327–341
- 73 Kumari, A. *et al.* (2010) Biodegradable polymeric nanoparticles based drug delivery systems. *Colloids Surf. B Biointerfaces* 75, 1–18
- 74 Sailor, M.J. and Park, J-H. (2012) Hybrid nanoparticles for detection and treatment of cancer. *Adv. Mater.* 24, 3779–3802
- 75 Danhier, F. *et al.* (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. *J. Control. Release* 148, 135–146
- 76 Lin, K. *et al.* (2013) Nanoparticles that sense thrombin activity as synthetic urinary biomarkers of thrombosis. *ACS Nano* 7, 9001–9009
- 77 Olson, E.S. *et al.* (2010) Activatable cell penetrating peptides linked to nanoparticles as dual probes for *in vivo* fluorescence and MR imaging of proteases. *Proc. Natl. Acad. Sci. U.S.A.* 107, 4311–4316
- 78 Cole, A.J. *et al.* (2011) Cancer theranostics: the rise of targeted magnetic nanoparticles. *Trends Biotechnol.* 29, 323–332
- 79 Derfus, A.M. *et al.* (2007) Remotely triggered release from magnetic nanoparticles. *Adv. Mater.* 19, 3932–3936
- 80 McCarthy, J.R. and Weissleder, R. (2008) Multifunctional magnetic nanoparticles for targeted imaging and therapy. *Adv. Drug Deliv. Rev.* 60, 1241–1251
- 81 Mo, S. *et al.* (2012) Ultrasound-enhanced drug delivery for cancer. *Exp. Opin. Drug Deliv.* 9, 1525–1538
- 82 Bagley, A.F. *et al.* (2013) Plasmonic photothermal heating of intraperitoneal tumors through the use of an implanted near-infrared source. *ACS Nano* 7, 8089–8097
- 83 von Maltzahn, G. *et al.* (2009) Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. *Cancer Res.* 69, 3892–3900
- 84 Cheng, Z. *et al.* (2012) Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. *Science* 338, 903–910
- 85 Eldar-Boock, A. *et al.* (2013) Nano-sized polymers and liposomes designed to deliver combination therapy for cancer. *Curr. Opin. Biotechnol.* 24, 682–689
- 86 Greco, F. and Vicent, M.J. (2009) Combination therapy: opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines. *Adv. Drug Deliv. Rev.* 61, 1203–1213
- 87 Nam, J. *et al.* (2013) pH-responsive assembly of gold nanoparticles and spatiotemporally concerted drug release for synergistic cancer therapy. *ACS Nano* 7, 3388–3402
- 88 von Maltzahn, G. *et al.* (2007) Nanoparticle self-assembly gated by logical proteolytic triggers. *J. Am. Chem. Soc.* 129, 6064–6065
- 89 Anglin, E.J. *et al.* (2008) Porous silicon in drug delivery devices and materials. *Adv. Drug Deliv. Rev.* 60, 1266–1277
- 90 Serda, R.E. *et al.* (2011) Multi-stage delivery nano-particle systems for therapeutic applications. *Biochim. Biophys. Acta* 1810, 317–329
- 91 Park, J-H. *et al.* (2010) Cooperative nanoparticles for tumor detection and photothermally triggered drug delivery. *Adv. Mater.* 22, 880–885
- 92 Godin, B. *et al.* (2010) An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. *Adv. Genet.* 69, 31–64
- 93 Ren, Y. *et al.* (2012) Identification and characterization of receptor-specific peptides for siRNA delivery. *ACS Nano* 6, 8620–8631
- 94 Cooper, S. *et al.* (2010) Predicting protein structures with a multiplayer online game. *Nature* 466, 756–760
- 95 Martinez-Veracoechea, F.J. and Frenkel, D. (2011) Designing super selectivity in multivalent nano-particle binding. *Proc. Natl. Acad. Sci. U.S.A.* 108, 10963–10968
- 96 Florence, A.T. (2012) Reductionism and complexity in nanoparticle-vectorized drug targeting. *J. Control. Release* 161, 399–402
- 97 Anderson, D.G. *et al.* (2006) A combinatorial library of photocrosslinkable and degradable materials. *Adv. Mater.* 18, 2614–2618
- 98 Green, J. *et al.* (2008) A combinatorial polymer library approach yields insight into nonviral gene delivery. *Acc. Chem. Res.* 41, 749–759
- 99 Valencia, P.M. *et al.* (2013) Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. *ACS Nano* 7, 10671–10680
- 100 Douglas, S.M. *et al.* (2009) Self-assembly of DNA into nanoscale three-dimensional shapes. *Nature* 459, 414–418

- 101 Douglas, S.M. *et al.* (2012) A logic-gated nanorobot for targeted transport of molecular payloads. *Science* 335, 831–834
- 102 Iinuma, R. *et al.* (2014) Polyhedra self-assembled from DNA tripods and characterized with 3D DNA-PAINT. *Science* 344, 65–69
- 103 Maune, H.T. *et al.* (2010) Self-assembly of carbon nanotubes into two-dimensional geometries using DNA origami templates. *Nat. Nanotechnol.* 5, 61–66
- 104 Amornphimoltham, P. *et al.* (2011) Intravital microscopy as a tool to study drug delivery in preclinical studies. *Adv. Drug Deliv. Rev.* 63, 119–128
- 105 Hak, S. *et al.* (2010) Intravital microscopy in window chambers: a unique tool to study tumor angiogenesis and delivery of nanoparticles. *Angiogenesis* 13, 113–130
- 106 Albanese, A. *et al.* (2013) Tumour-on-a-chip provides an optical window into nanoparticle tissue transport. *Nat. Commun.* 4, 2718
- 107 Lanza, R. *et al.* (2011) *Principles of Tissue Engineering*, Academic Press
- 108 Miller, J.S. *et al.* (2012) Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues. *Nat. Mater.* 11, 768–774